Author: Editor

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that radioembolization of colorectal cancer (CRC) liver-limited metastases is not ready for use in the first line. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that radioembolization of colorectal cancer (CRC) liver-limited metastases is ready for use in the first line. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that there is no optimal first-line therapy sequence in metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that there is an optimal sequence for first-line therapy in metastatic colorectal cancer (mCRC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that biomarkers do not have a role in the adjuvant setting for colorectal cancer. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses the use of biomarkers for colon cancer treatment selection. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Charles B. Simone examines novel forms of radation delivery, and whether technology can trump biology in the treatment of disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass arguest that a trimodality approach is preferred for the treatment of locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski proposes that a bimodality approarch is preferential for the treatment of locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski discusses whether or not the choice of systemic agents or their sequencing makes a different in combined modality therapy for locally-advanced non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass discusses the mangement of the mediastinum and other surgical issues. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentatino, Dr. Gerard A. Silvestri outlines his perspective on the updated TNM classifications for malignant tumors, and expounds upon whether there is a role for histology of markers. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology” Dr. Laura Jean Bierut examines current strategies for curtailing smoking addiction. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Benjamin Levy queries whether liquid biopsy will replace conventional tissue-based sampling. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. William K. Evans discusses the current cost and efficacy of managing non-small cell lung cancer (NSCLC). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7190 © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sven de Vos disuccese new agents for use in the treatment of recurrent follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg argues against the use of maintenance rituximab for the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Gilles Salles argues that maintenance rituxumab should be used in the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Thomas E. Witzig discusses how he sequence therapy in the treatment of follicular lymphoma (FL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jia Ruan examines the best approach to the initial therapy of peripheral t-cell lymphoma (PTCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presenation, Dr. Kami Maddocks discusses who should get what for upfront therapy of mantle cell lymphoma (MCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Adam M. Petrich discusses the best approach to treat double hit/double protein expression diffuse large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John P. Leonard discusses the hurdles to using cell of origin in the classification and treatment of diffuse large b-cell lymphoma (DLBCL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Laurie H. Sehn discusses the best approach to limited stage diffuse large b-cell lymphoma (DLBCL), and whether that includes radiation. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Randy Gascoyne discusses the future of lymphoma pathology in the era of tumor profliing. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg discusses the highlights from the 2015 International Conference on Malignant Lymphoma, held in Lugano Switzerland. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses including complete responses (CRs) in patients with chronic lymphocytic leukemia (CLL) following long-term treatment. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve M. Ansell discusses the use of immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien argues that there is no value to the use of brentuximab vedotin as consolidation therapy following auto-SCT in Hodgkin Lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies” Dr. Robert W. Chen argues that there is value to using brentuximab vedotin as consolidation therapy shorlty following auto-SCT in Hodgkin Lymphoma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jeremy Abramson argues that chemotherapy-based regiments are the preferred second-line approach to induce lymphoma remission prior to stem cell transplant (SCT). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Allison Moskowitz argues that single-agent brentuximab is the best second-line approach to induce lymphoma remission prior to stem cell transplant (SCT). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Giorgio Inghirami discusses whether or not we can use patient-derived xenografts to assess new lymphoma therapies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Irene M. Ghobrial discusses why Waldenstrom’s and myeloma change from monoclonal gammopathy of undetermine significane (MGUS) to active disease. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Esteban Braggio discusses how useful genomics is in the clinical practice, with regard to the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien disccusses patient selection criterion for allogeneic transplant as treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John Allan discusses the risks, predictors, and treatment of Richter’s Syndrome. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jennifer R. Brown discusses whether the incidence of familial chronic lymphocytic leukemia (CLL) is increasing. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman elucidates the different between the various techniques of using CAR-T cells for the treatment of chronic lymphocytic leukemia (CLL) A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Mitchell R. Smith discusses when and how to use FCR and BR in the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve Coutre discusses tyrosine-kinase inhibitors (TKIs), apoptotic enhancers, and other small molecules in the pipeline for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman discusses risk assessment in the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kanti Rai discuses the most recently approved tyrosine-kinase inhibitors (TKIs) for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Neil Kay discusses the targeted inhibition of signal molecules as a novel therapy for the treatment of chronic lymphocytic leukemia (CLL). A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kenneth C. Anderson discusses new paradigms and therapies for the treatment of relapsed/refracory myeloma. He discussesthe use fo small molecules and monoclonal antibodies. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Guentehr Koehne examines whether there is a role for allotransplant in the treatment of myeloma. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sundar Jagannath argues against maintenance therapy in the myeloma setting. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo argues in favor of the use of immunomodulatory drugs (IMiDs) for the maintenance of myeloma patients. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson argues that myeloma patients should be maintained with proteasome inhibitors. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2016 Imedex, LLC.

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Tomer Mark argues that it is not necessary for patients to achieve a complete remission (CR) and minimum residual disease (MRD), and that transplant is therefore unnecessary. A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP © 2015 Imedex, LLC.